ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 0.69 nM and 1.8 nM respectively.
Legal Status
As of October 2015 ADBICA is a controlled substance in China.
See also
5F-AB-PINACA 5F-ADB 5F-ADBICA 5F-AMB 5F-APINACA AB-FUBINACA AB-CHFUPYCA AB-CHMINACA AB-PINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADB-P7AICA APICA APINACA MDMB-CHMICA PF-03550096 STS-135 PX-3
References